Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

[1]  K. Yokote,et al.  Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database , 2021, Journal of diabetes investigation.

[2]  J. Sasaki,et al.  Sitagliptin Improves Plasma Apolipoprotein Profile in Type 2 Diabetes: A Randomized Clinical Trial of Sitagliptin Effect on Lipid and Glucose Metabolism (SLIM) Study. , 2020, Diabetes research and clinical practice.

[3]  M. Sugawara,et al.  Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia , 2018, Journal of diabetes investigation.

[4]  Satoko Nakamura,et al.  The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial , 2018, Clinical and Experimental Nephrology.

[5]  J. Oyama,et al.  Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus , 2018, Geriatrics & gerontology international.

[6]  H. Sakura,et al.  Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study , 2017, Journal of clinical medicine research.

[7]  H. Sakura,et al.  Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study , 2017, Diabetology International.

[8]  Yuichiro Yamada,et al.  Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial) , 2017, Diabetes, obesity & metabolism.

[9]  H. Heerspink,et al.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. , 2017, Journal of the American Society of Nephrology : JASN.

[10]  M. Haneda.  Committee Report: Glycemic targets for elderly patients with diabetes , 2017, Journal of diabetes investigation.

[11]  Glycemic Targets for Elderly Patients with Diabetes , 2016, Geriatrics & gerontology international.

[12]  Y. Shentu,et al.  A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control , 2016, Journal of diabetes.

[13]  M. Diamant,et al.  Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2016, Diabetes Care.

[14]  Chris I. Jones.  Platelet function and ageing , 2016, Mammalian Genome.

[15]  P. Crane,et al.  Glucose Levels and Risk of Frailty. , 2016, The journals of gerontology. Series A, Biological sciences and medical sciences.

[16]  S. Mangia,et al.  Impact of diabetes on cognitive function and brain structure , 2015, Annals of the New York Academy of Sciences.

[17]  S. Ito,et al.  Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study , 2015, BMC Endocrine Disorders.

[18]  T. Hansen,et al.  Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. , 2015, Journal of diabetes and its complications.

[19]  T. Ninomiya,et al.  Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study , 2015, Cardiovascular Diabetology.

[20]  Y. Terauchi,et al.  Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes. , 2015, Diabetes research and clinical practice.

[21]  S. Seino,et al.  β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians , 2015, Current Diabetes Reports.

[22]  H. Itoh,et al.  Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial , 2015, PloS one.

[23]  D. Giugliano,et al.  A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients , 2015, BMJ Open.

[24]  M. Koga.  Glycated albumin; clinical usefulness. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[25]  M. Diamant,et al.  The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? , 2014, Nature Reviews Nephrology.

[26]  S. Haneuse,et al.  Glucose levels and risk of dementia. , 2013, The New England journal of medicine.

[27]  H. Tamura,et al.  Association of glycated albumin with the presence of carotid plaque in patients with type 2 diabetes , 2013, Journal of diabetes investigation.

[28]  Nathaniel Clark,et al.  Diabetes in Older Adults: A Consensus Report , 2012, Journal of the American Geriatrics Society.

[29]  H. Nakano,et al.  Non‐high‐density lipoprotein cholesterol: An important predictor of stroke and diabetes‐related mortality in Japanese elderly diabetic patients , 2012, Geriatrics & gerontology international.

[30]  H. Nakano,et al.  Long‐term multiple risk factor interventions in Japanese elderly diabetic patients: The Japanese Elderly Diabetes Intervention Trial – study design, baseline characteristics and effects of intervention , 2012, Geriatrics & gerontology international.

[31]  N. Barzilai,et al.  Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial , 2011, Current medical research and opinion.

[32]  C. Koliaki,et al.  Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus , 2011, Diabetes therapy : research, treatment and education of diabetes and related disorders.

[33]  J. Rosenstock,et al.  Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[34]  Kristine Yaffe,et al.  Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. , 2009, JAMA.

[35]  H. Kaneto,et al.  Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. , 2008, Endocrine journal.

[36]  Frank A Sloan,et al.  Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. , 2007, Archives of internal medicine.

[37]  Ronald Brazg,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2006, Clinical therapeutics.

[38]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[39]  A. Huber,et al.  Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. , 2004, The Journal of clinical endocrinology and metabolism.